Review Article

Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis

Dong Wu, Shu-Mei Wu, Jie Lu, Ying-Qun Zhou, Ling Xu, and Chuan-Yong Guo

Department of Gastroenterology, Shanghai tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China

Correspondence should be addressed to Ling Xu; xuling606@sina.com and Chuan-Yong Guo; guochuanyong@hotmail.com

Received 14 December 2012; Revised 7 March 2013; Accepted 7 March 2013

Academic Editor: Edoardo Giovanni Giannini

Copyright © 2013 Dong Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Many studies have found that the antibiotic rifaximin is effective for the treatment of hepatic encephalopathy. However, there is no uniform view on the efficacy and safety of rifaximin. Methods. We performed a meta-analysis through electronic searches to evaluate the efficacy and safety of rifaximin in comparison with nonabsorbable disaccharides. Results. A total of 8 randomized controlled trials including 407 patients were included. The efficacy of rifaximin was equivalent to nonabsorbable disaccharides according to the statistical data (risk ratio (RR): 1.06, 95% CI: 0.94–1.19; P = 0.34). Analysis showed that patients treated with rifaximin had better results in serum ammonia levels (weighted mean difference (WMD): −10.63, 95% CI: −30.63–9.38; P = 0.30), mental status (WMD: −0.32, 95% CI: −0.67–0.03; P = 0.07), asterixis (WMD: −0.12, 95% CI: −0.31–0.08; P = 0.23), electroencephalogram response (WMD: −0.21, 95% CI: −0.34–−0.09; P = 0.0007), and grades of portosystemic encephalopathy (WMD: −2.30, 95% CI: −2.78–−1.82; P < 0.00001), but only the last ones had statistical significance. The safety of rifaximin was better than nonabsorbable disaccharides (RR: 0.19, 95% CI: 0.10–0.34; P < 0.00001). Conclusion. Rifaximin is at least as effective as nonabsorbable disaccharides, maybe better for the treatment of hepatic encephalopathy. And the safety of rifaximin is better.

1. Introduction

Hepatic encephalopathy (HE) is a complex and reversible neuropsychiatric syndrome that results from acute or chronic liver diseases, such as hepatic cirrhosis, alcoholic liver disease [1]. HE is an important complication of hepatic cirrhosis and is an independent predictor of mortality in patients with cirrhosis [2]. HE occurs in the presence of insufficient hepatic clearance of toxins absorbed from the intestine resulting in neurochemical abnormalities across the blood brain barrier [3]. The symptoms of HE, manifested on a continuum, are deterioration in mental status, with psychomotor dysfunction, impaired memory, increased reaction time, sensory abnormalities, poor concentration, disorientation, even coma, and death [4, 5]. Overt HE means high mortality and poor prognosis. 1-year mortality for patients with severe HE in ICU is 54% [6]. Episodes of overt HE result in frequent hospitalizations and pose a formidable burden on the healthcare system, especially in China, a developing country with 100,000,000 hepatitis B carriers [7].

Diagnosis of overt hepatic encephalopathy should be made after the exclusion of other brain disorders [8] and based on two types of symptoms. Impaired mental status, as defined by the Conn score, with higher scores indicating more severe impairment, and impaired neuromotor function includes hyperreflexia, rigidity, myoclonus, and asterixis [9, 10]. Minimal hepatic encephalopathy (MHE) that may have no clinical manifestations could be detected only by neuropsychological methods include portosystemic encephalopathy (PSE) syndrome test, Psychometric-Hepatic-Encephalopathy-Sum- (PHES-) Score [11]. Elevated serum ammonia level is an effective index of HE and is detected in 60%–80% of affected patients, but a single ammonia level in the diagnosis of HE is uncertain given the substantial overlap of ammonia levels in both patients with and without encephalopathy [12]. Current treatment strategies include measures aimed at reducing the serum level of ammonia, providing specialized nursing care as well as correcting precipitating factors such as gastrointestinal hemorrhage, infection, constipation, and electrolyte disturbances [5].
Up to now, nonabsorbable disaccharides such as lactulose (β-galactoside fructose) and lactitol (β-galactoside sorbitol) have been the first-line drug for the treatment of HE. They are directed at reducing the serum level of ammonia, since they decrease the absorption of ammonia through cathartic effects and by altering the colonic pH [13]. The side effects of nonabsorbable disaccharides include abdominal pain, flatulence, and severe diarrhea, which may lead to the cessation of therapy [14]. Antibiotics such as neomycin, vancomycin, metronidazole, and rifaximin were shown to be effective in the treatment of both acute and chronic encephalopathy. They reduce bacterial production of ammonia through suppression of intestinal flora [15,16]. Due to serious side effects such as ototoxicity and nephrotoxicity, most antibiotics exception of rifaximin are not suitable for long-term use for the treatment of HE [17]. Rifaximin is a minimally absorbed oral gastrointestinal selective antibiotic, with very few systemic side effects and has a low risk of inducing bacterial resistance [18]. Some studies showed that rifaximin is superior to lactulose and antimicrobials in patients with mild-to-moderate severe HE [19], but a larger meta-analysis including twelve studies comparing rifaximin to conventional oral therapy showed no significant difference between the two interventions [20]. Previous studies have reached different conclusions, therefore, we conducted a meta-analysis to evaluate all RCTs comparing rifaximin to nonabsorbable disaccharides for the treatment of patients with HE.

2. Methods

2.1. Search Strategy and Study Selection. The Pubmed, EMBase, Cochrane Library, EMBASE, CINAHL, and Science Citation Index (ISI Web of Science) were searched to collect all randomized controlled trials comparing rifaximin to nonabsorbable disaccharides for the treatment of hepatic encephalopathy (last search update: 20th August 2012) without language restriction.

Database specific search terms for rifaximin (rifaximin, rifamycins), disaccharides (disaccharides, lactulose, lactitol, and sugar alcohols) were combined by limiting the searches to studies of human patients and reports of clinical trials. All reference lists of eligible studies were hand-searched to avoid missing any relevant studies. Two reviewers (Dong Wu and Shu-Mei Wu) independently assessed the eligibility of all potential abstracts and titles.

2.2. Inclusion and Exclusion Criteria. Inclusion criteria were (1) patient population over 18 years of age; (2) signs and symptoms of acute, chronic HE according to Conn's modification of Parsons Smith classification [21]. Inclusion was regardless of publication status, language. Exclusion criteria were (1) non-controlled clinical trial; (2) trials including patients and with psychiatric illness, with undercurrent infections, with hypersensitivity to rifaximin and other antibiotics and/or intolerance to nonabsorbable disaccharides; (3) studies that compared the use of rifaximin versus placebo; (4) trials that included individuals affected by gastrointestinal bleeding.

2.3. Definitions. Clinical efficacy was defined as improvement in the HE clinical syndrome as in passing to a lower stage or a significant decrease in the portosystemic encephalopathy index. Partial neurological response was measured by mental status scores according to Conn's classification [21,22], and adverse events in this study were severe diarrhea, episodes of intense abdominal pain. Serum ammonia levels were assessed at the end of the treatment. The severity of asterixis was graded according to established criteria as follows: 0, no tremors; 1, few flapping motions; 2, occasional flapping motions; 3, frequent flapping motions; and 4, almost continuous flapping motions. Electroencephalogram (EEG) abnormalities recorded in patients with HE were scored according to criteria as follows: 0, normal EEG; 1, normal limit EEG; 2, mild signs of encephalopathy; 3, distinctive features of encephalopathy; and 4, signs of severe encephalopathy. Grades of PSE were calculated as the sum of the degree of mental status abnormality scores, the severity of asterixis, level of serum ammonia, and the degree of EEG abnormality [23].

2.4. Data Extraction. Two authors extracted information independently, and disagreements were resolved by discussion. The following data were extracted from each included article: name of the first author, year of publication, country of origin, number of patients, daily dosage of oral therapy, duration of the treatment, allocation sequence generation, and methods used to deal with missing data. Clinical variables extracted were the effectiveness of rifaximin and non-absorbable disaccharides, side effects, serum ammonia levels, and psychometric parameters.

2.5. Assessment of Methodological Quality. The quality of each study was assessed according to the Cochrane Collaboration's tool for assessing risk of bias. Each of the items in the checklist was scored as "yes", "no", "unclear", or "not available" [24].

2.6. Statistical Analysis. Statistical analyses were performed using RevMan Version 5.0.5 software. The effect measures estimated were risk ratio (RR) for dichotomous data and weighted mean difference (WMD) for continuous data, both reported with 95% confidence intervals (CIs). Pooled RR or WMD was calculated using the general inverse variance (IV) with random effect model. The heterogeneity between studies was examined by DerSimonian and Laird (DL) Q statistical analysis. If results were heterogeneous \( P < 0.1 \), random effect model was used with the DL methods. Pooled RR or WMD was presented as standard plots with 95%.

3. Results

A total of 175 potentially relevant references were identified with only eight being controlled clinical trials (Figure 1) [21,25–31]. The outcomes were extracted from each trial. The main characteristics of the trials included in the meta-analysis are shown in Table 1. Most clinical trials were single-center...
Records identified through database searching in PubMed, Embase, CINAHL, and Science Citation Index  
\( n = 175 \)

Records after duplicates removed  
\( n = 87 \)

Records screened  
\( n = 35 \)

Full-text articles assessed for eligibility  
\( n = 8 \)

Records excluded  
\( n = 52 \)
- Reviews or editorials  
\( n = 15 \)
- Decision analysis  
\( n = 5 \)
- Studies on animals  
\( n = 9 \)
- No original paper  
\( n = 12 \)
- Others  
\( n = 11 \)

Studies included in qualitative synthesis  
\( n = 8 \)

Full-text articles excluded, with reasons  
\( n = 27 \)
- Insufficient data  
\( n = 17 \)
- Uncontrolled clinical trials  
\( n = 7 \)
- Double publication  
\( n = 3 \)

Studies included in quantitative synthesis (meta-analysis)  
\( n = 8 \)
- Rifaximin versus lactulose  
\( n = 6 \)
- Rifaximin versus lactitol  
\( n = 2 \)

**Figure 1:** Flow diagram of included studies of meta-analysis.

**Table 1:** RCTs with rifaximin (1200 mg/day) in the treatment of hepatic encephalopathy.

| Authors            | Country   | Year | Rifaxim (n) | Control (n) | Comparative agent | Duration of treatment | Outcomes                                                                 |
|--------------------|-----------|------|-------------|-------------|--------------------|----------------------|--------------------------------------------------------------------------|
| Paik et al. [21]   | South Korea | 2005 | 32          | 22          | Lactulose 90 mL/d  | 7 d                  | Mental status, flapping tremors, NCT, blood ammonia, and HE index       |
| Verhagen et al. [24]| Italy     | 2001 | 9           | 12          | Lactulose 60 mL/d  | 21 d                 | Asterixis, EEG, blood ammonia                                           |
| Festi et al. [25]  | Italy     | 1993 | 20          | 20          | Lactulose 45 mL/d  | 15 d                 | Mental status, asterixis, cancellation test, Reitan test, EEG, and blood ammonia |
| Bucci and Palmieri [26]| Italy     | 1993 | 20          | 20          | Lactulose 90 mL/d  | 15 d                 | Mental status, asterixis, cancellation test, EEG, trail making test, PSE index, and blood ammonia |
| Massa et al. [27]  | Spain     | 1993 | 50          | 53          | Lactitol 60 g/d    | 5–10 d               | HE grade, mental status, asterixis, NCT, EEG, PSE index, and blood ammonia |
| Mas et al. [28]    | Italy     | 2003 | 14          | 13          | Lactulose 90 g/d   | 3 month              | Mental status, asterixis, NCT, and blood ammonia                        |
| Loguercio et al. [29]| Italy     | 2003 | 20          | 20          | Lactulose 120 mL/d | 3 month              | Mental status, asterixis, cancellation test, Reitan test, EEG, and PSE severity |
| Fera et al. [30]   | South Korea | 1993 | 39          | 25          | Lactulose 90 mL/d  | 7 d                  | Blood ammonia, mental status, flapping tremors, NCT, and HE index       |

NCT: number connection test, EEG: electroencephalogram, and PSE: portosystemic encephalopathy.
except one, which was multicentric [25]. The dose of rifaximin was usually 1200 mg/day, and the dose of nonabsorbable disaccharides ranged from 45 to 120 mL/d for lactulose and 60 g/d for lactitol.

The quality assessments of the eight randomized controlled trials (RCTs) are shown in Table 2. The allocation system was described in five trials, and allocation concealment was defined in six trials. All the trials were blinded to patients; however, only three trials were blinded to observers. Methods for handling missing data, description of drop-outs were not described in any of the included studies.

3.1. Primary Outcomes

3.1.1. Efficacy. Clinical efficacy was defined as improvement in the HE clinical syndrome as in passing to a lower stage or a significant decrease in the portosystemic encephalopathy index. HE index = (grade of mental state) × 3 + (grade of number connection test) + (grade of flapping tremor) + (grade of blood ammonia) [32]. As the RCT reported by Bucci did not mention the number of patients with clinical efficacy, we only had seven RCTs to assess the effectiveness by comparing rifaximin to nonabsorbable disaccharides. Using the random-effect model (χ² = 11.57, df = 6 (P = 0.07), I² = 48% < 50%), the pooled analysis of seven trials that investigated the efficacy of rifaximin (n = 184) versus nonabsorbable disaccharides (n = 165) showed no significant difference (RR: 1.06, 95% CI: 0.94–1.19; P = 0.34) (Figure 2).

3.1.2. Safety or Adverse Events. In our meta-analysis, two common side effects were assessed: severe diarrhea and abdominal pain. The adverse events were pooled and compared between the group of rifaximin (n = 390) and the control group (n = 342). A subgroup analysis was done to compare each side effect separately. Patients in rifaximin group had less risk of suffering from diarrhea (RR: 0.11, 95% CI: 0.04–0.31; P < 0.0001). The rate of abdominal pain was also lower in rifaximin group (RR: 0.34, 95% CI: 0.14–0.83; P = 0.02). Obviously, combined analysis of two adverse events showed that rifaximin was safer than nonabsorbable disaccharides for the treatment of hepatic encephalopathy (RR: 0.19, 95% CI: 0.10–0.37; P = 0.00001) (Figure 3).

3.2. Secondary Outcomes. Psychometric parameters: there was no significant difference in the improvement in mental status and grade of asterixis (rifaximin versus control) (P = 0.07 and P = 0.23, resp.). For EEG and PSE sum, our analysis showed statistically significant difference favoring the use of rifaximin (P = 0.0007, P < 0.00001, resp.) (Table 3).

Blood ammonia level: we extracted blood ammonia level at the end of 4 RCTs [21, 25, 26, 28], a significant reduction in serum ammonia level was observed in both treatment groups (rifaximin versus nonabsorbable disaccharides); however, there was no significant difference (WMD: −10.63, 95% CI: −30.63–9.38; P = 0.30) (Figure 4).

3.3. Sensitivity Analysis. The ethnic differences and the presence of acute or chronic HE were important factors that might influence the effectiveness of rifaximin; we compared clinical efficacy among patients of Europe, patients with acute or chronic HE, respectively. Sensitivity analysis showed that the ethnic differences and the presence of acute HE did not influence the efficacy of rifaximin (P = 0.07, P = 0.70, resp.); however, significant difference in the treatment of acute HE, favoring the use of rifaximin (P = 0.005) (Table 4).

3.4. Publication Bias. Figure 5 showed the funnel plot of meta-analysis. The points were not uniformly distributed on both sides of the longitudinal axis, suggesting the presence of publication bias.

4. Discussion

Chronic liver disease and cirrhosis affect hundreds of millions of patients all over the world, especially in China. One of these recurrent and difficult to treat complications is hepatic encephalopathy [33]. Overt hepatic encephalopathy affects from 30 to 45% of patients with cirrhosis, and a higher percentage may be affected by minimal hepatic encephalopathy (MHE). It is a spectrum ranging from minimal hepatic encephalopathy (MHE) without recognizable clinical symptoms to overt HE with risk of cerebral edema and death. HE that results in diminished quality of life and survival is serious challenges on the healthcare system [7]. Our treatment strategy is to reduce the production and absorption of ammonia and other gut-derived toxins. Many overt HE can be improved when precipitating factors are corrected, such as infection, gastrointestinal bleeding, dehydration, and electrolyte disturbances [5]. Nonabsorbable disaccharides (lactulose and lactitol) were considered as standard treatment for hepatic encephalopathy, that have been proved effectively for the treatment of HE. Some severe adverse events, including diarrhea, abdominal pain, vomiting, and flatulence, may lead to the cessation of therapy with disaccharides. Some minimally absorbed antibiotics, such as neomycin, vancomycin, metronidazole, and oral quinolones, were previously shown in some studies to be effective in the treatment of both acute and chronic encephalopathy [16]. The significant risk of severe toxicity is the reason why most agents are seldom used in practice. Rifaximin is a minimally absorbed antimicrobial agent with a broad spectrum against gram-positive and gram-negative aerobic and anaerobic enteric bacteria [34]. Rifaximin seems to be the ideal drug that appears to be effective in the treatment of HE without carrying the risk of severe side effects. In 2010, FDA approved rifaximin as a drug of HE treatment. Is it reasonable to consider rifaximin as a first-line drug for HE? There is no consensus on it. Expense of rifaximin is great, and effectiveness of rifaximin is uncertain compared to nonabsorbable disaccharides. Results of some underpowered randomized controlled trials were inconsistent.

Here, we performed a meta-analysis containing eight randomized controlled trials assessing the efficacy and safety of rifaximin versus nonabsorbable disaccharides. Furthermore, we assessed the reduction of blood ammonia levels, and psychometric outcomes (mental status, grade of asterixis, and grade of blood ammonia) [32]. As the RCT reported by Bucci did not mention the number of patients with clinical efficacy, we only had seven RCTs to assess the effectiveness by comparing rifaximin to nonabsorbable disaccharides. Using the random-effect model (χ² = 11.57, df = 6 (P = 0.07), I² = 48% < 50%), the pooled analysis of seven trials that investigated the efficacy of rifaximin (n = 184) versus nonabsorbable disaccharides (n = 165) showed no significant difference (RR: 1.06, 95% CI: 0.94–1.19; P = 0.34) (Figure 2).
| Study or subgroup | Rifaximin | Control | Weight | Risk ratio | Risk ratio |
|------------------|-----------|---------|--------|------------|------------|
|                  | Events    | Total   | Events | Total       | M-H, random, 95% CI | M-H, random, 95% CI |
| Fera 1993        | 20        | 20      | 16     | 20         | 14.4%       | 124 [0.98, 1.57] |
| Festi 1993       | 9         | 9       | 12     | 12         | 18.6%       | 1.00 [0.84, 1.20] |
| Loguercio 2003   | 8         | 14      | 2      | 13         | 0.8%        | 3.71 [0.96, 14.37] |
| Mas 2003         | 40        | 50      | 41     | 53         | 16.7%       | 103 [0.85, 1.26] |
| Massa 1993       | 20        | 20      | 18     | 20         | 19.3%       | 1.11 [0.93, 1.31] |
| Paik 2005        | 27        | 32      | 21     | 22         | 19.0%       | 088 [0.74, 105]   |
| Song 2000        | 32        | 39      | 18     | 25         | 11.3%       | 1.14 [0.86, 1.52] |
| **Total (95% CI)** | 184      | 165     |        |            | 100.0%      | 1.06 [0.94, 1.19] |
| **Total events** | 156       | 128     |        |            |             |               |

Heterogeneity: Tau² = 0.01; Chi² = 11.57; df = 6 (P = 0.07); I² = 48%
Test for overall effect: Z = 0.95 (P = 0.34)

**Figure 2:** Efficacy of rifaximin versus nonabsorbable disaccharides in the treatment of hepatic encephalopathy. M-H: Mantel Haenszel.

| Study or subgroup | Rifaximin | Control | Weight | Risk ratio | Risk ratio |
|------------------|-----------|---------|--------|------------|------------|
|                  | Events    | Total   | Events | Total       | M-H, fixed, 95% CI | M-H, fixed, 95% CI |
| 2.1.1 diarrhea    |           |         |        |             |             |               |
| Bucci 1993       | 0         | 30      | 15     | 28         | 30.8%       | 0.03 [0.00, 0.48] |
| Loguercio 2003   | 0         | 14      | 0      | 13         | Not estimable |               |
| Mas 2003         | 2         | 50      | 1      | 53         | 1.9%        | 2.12 [0.20, 2266] |
| Massa 1993       | 0         | 20      | 13     | 20         | 26.0%       | 0.04 [0.00, 0.58] |
| Paik 2005        | 0         | 32      | 1      | 22         | 3.4%        | 0.23 [0.01, 5.45] |
| Song 2000        | 0         | 39      | 1      | 25         | 3.5%        | 0.22 [0.01, 5.12] |
| **Subtotal (95% CI)** | 185      | 161     |        |            | 65.6%       | 0.11 [0.04, 0.31] |
| **Total events** | 2         | 31      |        |            |             |               |

Heterogeneity: Chi² = 7.75; df = 4 (P = 0.10); I² = 48%
Test for overall effect: Z = 4.19 (P < 0.0001)

2.1.2 abdominal pain

| Study or subgroup | Rifaximin | Control | Weight | Risk ratio | Risk ratio |
|------------------|-----------|---------|--------|------------|------------|
|                  | Events    | Total   | Events | Total       | M-H, fixed, 95% CI | M-H, fixed, 95% CI |
| Bucci 1993       | 2         | 30      | 1      | 28         | 2.0%        | 1.87 [0.18, 19.47] |
| Fera 1993        | 0         | 20      | 10     | 20         | 20.2%       | 0.05 [0.00, 0.76] |
| Loguercio 2003   | 0         | 14      | 0      | 13         | Not estimable |               |
| Mas 2003         | 1         | 50      | 0      | 53         | 0.9%        | 3.18 [0.13, 76.20] |
| Massa 1993       | 0         | 20      | 3      | 20         | 6.7%        | 0.14 [0.01, 2.60] |
| Paik 2005        | 0         | 32      | 1      | 22         | 3.4%        | 0.23 [0.01, 5.45] |
| Song 2000        | 1         | 39      | 0      | 25         | 1.2%        | 1.95 [0.08, 46.07] |
| **Subtotal (95% CI)** | 205      | 181     |        |            | 34.4%       | 0.34 [0.14, 0.83] |
| **Total events** | 4         | 15      |        |            |             |               |

Heterogeneity: Chi² = 7.44; df = 5 (P = 0.19); I² = 33%
Test for overall effect: Z = 2.35 (P = 0.02)

Total (95% CI)

| Study or subgroup | Rifaximin | Control | Weight | Risk ratio | Risk ratio |
|------------------|-----------|---------|--------|------------|------------|
|                  | Events    | Total   | Events | Total       | M-H, random, 95% CI | M-H, random, 95% CI |
|                  |           |         |        |             |             |               |
| **Total events** | 6         | 46      |        |             |             |               |

Heterogeneity: Chi² = 16.79; df = 10 (P = 0.08); I² = 40%
Test for overall effect: Z = 4.92 (P < 0.00001)
Test for subgroup differences: Chi² = 2.51; df = 1 (P = 0.11); I² = 60.2%

**Figure 3:** Adverse events of rifaximin versus nonabsorbable disaccharides in the treatment of hepatic encephalopathy. M-H: Mantel Haenszel.
| Study or subgroup | Rifaximin Mean | SD | Total | Control Mean | IV, random, 95% CI | Weight | Mean difference | IV, random, 95% CI | Mean difference |
|------------------|---------------|----|-------|--------------|-------------------|--------|----------------|-------------------|----------------|
| Bucci 1993       | 74            | 4  | 30    | 78           | 7                 | 28     | 27.7%          | −4.00 [−69.6, −1.04] |
| Festi 1993       | 46            | 6  | 9     | 48           | 6                 | 12     | 27.4%          | −2.00 [−7.19, 3.19] |
| Mas 2003         | 70            | 13 | 50    | 109          | 12                | 53     | 27.5%          | −39.00 [−43.84, −34.16] |
| Paik 2005        | 138           | 61 | 32    | 128          | 49                | 22     | 174%           | 10.00 [−19.43, 39.43] |
| **Total (95% CI)** | 121           |    | 115   | 100.0%       | −10.63            |        |                | −10.63 [−30.63, 9.38] |

Heterogeneity: \( \tau^2 = 373.27; \chi^2 = 163.55; \text{df} = 3 (P < 0.0001); I^2 = 98\%

Test for overall effect: \( Z = 1.04 \) (\( P = 0.30 \))

**FIGURE 4:** Blood ammonia levels at the end of treatment: rifaximin versus nonabsorbable disaccharides. IV: inverse variance.

**FIGURE 5:** Funnel plot of meta-analysis. (a): effectiveness, (b): adverse events and (c): blood ammonia level.
Table 2: Summary of methodological quality of included studies on the basis of review authors’ judgments.

| Included studies            | Allocation system | Allocation concealment | Patient | Blind observer | Assessor | Handling of missing data |
|-----------------------------|-------------------|------------------------|---------|----------------|----------|--------------------------|
| Paik et al. 2005 [21]       | Yes               | Yes                    | Yes     | No             | NA       | Unclear                  |
| Festi et al. 1993 [25]      | No                | No                     | Yes     | No             | NA       | Unclear                  |
| Bucci and Palmieri 1993 [26]| Yes               | Yes                    | Yes     | Yes            | Yes      | NA                       |
| Massa et al. 1993 [27]      | No                | Yes                    | Yes     | No             | NA       | Unclear                  |
| Mas et al. 2003 [28]        | Yes               | Yes                    | Yes     | Yes            | Yes      | NA                       |
| Loguercio et al. 2003 [29]  | No                | No                     | Yes     | No             | NA       | Unclear                  |
| Fera et al. 1993 [30]       | Yes               | Yes                    | Yes     | No             | NA       | Unclear                  |
| Song et al. 2000 [31]       | Yes               | Yes                    | Yes     | No             | NA       | Unclear                  |

NA: not available.

Table 3: Meta-analysis of psychometric outcomes between rifaximin and nonabsorbable disaccharides.

| Psychometric outcomes | Rifaximin Mean | SD | Total | Control Mean | SD | Total | Mean difference IV, random, 95% CI |
|-----------------------|---------------|----|-------|--------------|----|-------|-----------------------------------|
| Mental status         | 0.8           | 0.5 | 30     | 1.2          | 0.3 | 28     | -0.40 [-0.61, -0.19] |
| Asterix               | 0.5           | 0.3 | 30     | 1.2          | 0.3 | 28     | -0.40 [-0.61, -0.19] |
| EEG                   | 0.4           | 0.2 | 30     | 0.6          | 0.3 | 28     | -0.20 [-0.33, -0.07] |
| PSE sum               | 4             | 0.1 | 50     | 6            | 2   | 53     | -2.00 [-2.54, -1.46] |

Heterogeneity: $T^2 = 0.10; \chi^2 = 22.09; df = 3 (P < 0.0001); I^2 = 86%$
Test for overall effect: $Z = 1.80 (P = 0.07)$

Heterogeneity: $T^2 = 0.03; \chi^2 = 10.85; df = 3 (P = 0.01); I^2 = 72%$
Test for overall effect: $Z = 1.19 (P = 0.23)$

IV: inverse variance, EEG: electroencephalogram, and PSE: portosystemic encephalopathy.
severe adverse events in disaccharides therapy could use sive price and safety in long-term use. Patients who have inmin should be used as second-line, because of expen-
notcredible because of small samples. We suggest that rifax-
analysis showed significant difference in the treatment of nonabsorbable disaccharides, maybe better in some psy-
patients are necessary to obtain more sufficient evidence for changes in the treatment of HE. Of course, there were some
accuratescoringcriteriatoassessandquantifysubtleclinical
had low serum ammonia levels, superior mental status, and asterixis profiles versus the control group with no statistical
grade of EEG and PSE
risk of hospitalization involving hepatic encephalopathy [35].
So, rifaximin is effective in the treatment and prevention of hepatic encephalopathy, but more studies are needed to assess its safety, including tolerance, toxicity, bacterial resistance, and mycotic infection.

For the secondary outcomes, patients in rifaximin group had lower serum ammonia levels, superior mental status, and asterixis profiles versus the control group with no statistical significance. On the other hand, the grade of EEG and PSE sums showed better results for patients in rifaximin group, when compared to their controls. So, maybe we can build an accurate scoring criteria to assess and quantify subtle clinical changes in the treatment of HE. Of course, there were some limitations in our meta-analysis. The RCTs included in our study did not have enough number of cases. We need more RCTs in recent years to make the conclusion more convincing. Five of the eight RCTs were carried out in Italy, and there were little information about other countries. These reasons will lead to bias. So, further studies on larger populations of patients are necessary to obtain more sufficient evidence for the evaluation of rifaximin versus nonabsorbable disaccharides for HE.

In summary, this study shows that rifaximin is as effective as nonabsorbable disaccharides, maybe better in some psychometric outcomes, with fewer adverse events. Sensitivity analysis showed significant difference in the treatment of acute HE, favoring the use of rifaximin, but the result may be not credible because of small samples. We suggest that rifaximIn should be used as second-line, because of its expensive price and safety in long-term use. Patients who have severe adverse events in disaccharides therapy could use rifaximin instead.

Conflict of Interests

The authors have declared that there is no conflict of interests.

Table 4: Result of sensitivity analysis.

| Variable                  | Patients (rifaximin/control) | Pooled RR | P  |
|---------------------------|-------------------------------|-----------|----|
| All in Europe [24–29]     | 231 (113/118)                 | 3.16 [0.92, 10.93] | 0.07 |
| Acute HE [21, 27, 30]     | 157 (82/75)                   | 0.77 [0.20, 2.93] | 0.70 |
| Chronic HE [26, 28, 29]   | 107 (54/53)                   | 7.6 [1.87, 30.78] | 0.005 |

HE: hepatic encephalopathy; control lactulose or lactitol; RR: relative risk.

Authors’ Contributions

Dong Wu, Shu-Mei Wu Conceived and designed the experiments. Dong Wu, Shu-Mei Wu analyzed the data. Ling Xu, Chuan-Yong Guo contributed reagents/materials/analysis tools. Jie Lu, Ying-Qun Zhou wrote the paper. Dong Wu and Shu-Mei Wu contributed equally to this paper.

Acknowledgment

This study was supported by the National Natural Science Foundation of China (Grant no. 81270515, 8101579, 81072005, 81172312), Shanghai Science and Technology Foundation (Grant no. 11430702400), Chinese Foundation for Hepatitis Prevention and Control the WBN Research Foundation (Grant no. 20100021), Shanghai Municipal Health Bureau Foundation (Grant no. 2011287, 2012107).

References

[1] J. Bustamante, A. Rimola, P. J. Ventura et al., “Prognostic significance of hepatic encephalopathy in patients with cirrhosis,” Journal of Hepatology, vol. 30, no. 5, pp. 890–895, 1999.
[2] H. Garg, A. Kumar, V. Garg, P. Sharma, B. C. Sharma, and S. K. Sarin, “Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure,” Digestive and Liver Disease, vol. 44, pp. 166–171, 2012.
[3] S. Abou-Assi and Z. R. Vlahcevic, “Hepatic encephalopathy: metabolic consequence of cirrhosis often is reversible,” Postgraduate Medicine, vol. 109, no. 2, pp. 52–65, 2001.
[4] C. A. Stewart, M. Malinchoc, W. R. Kim, and P. S. Kamath, “Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease,” Liver Transplantation, vol. 13, no. 10, pp. 1366–1371, 2007.
[5] P. Ferenci, A. Lockwood, K. Mullen, R. Tarter, K. Weissenborn, and A. T. Blei, “Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998,” Hepatology, vol. 35, no. 3, pp. 716–721, 2002.
[6] J. Fichet, E. Mercier, O. Genée et al., “Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy,” Journal of Critical Care, vol. 24, no. 3, pp. 364–370, 2009.
[7] Z. Poh and P. E. Chang, “A current review of the diagnostic and treatment strategies of hepatic encephalopathy,” International Journal of Hepatology, vol. 2012, Article ID 480309, 10 pages, 2012.
[8] M. J. W. McPhail, J. S. Bajaj, H. C. Thomas, and S. D. Taylor-Robinson, “Pathogenesis and diagnosis of hepatic encephalopathy,” Expert Review of Gastroenterology and Hepatology, vol. 4, no. 3, pp. 365–378, 2010.
[9] G. W. Neff, M. Jones, T. Broda et al., “Durability of rifaximin response in hepatic encephalopathy,” Journal of Clinical Gastroenterology, vol. 46, no. 2, pp. 168–171, 2012.
[10] R. Williams, O. F. W. James, T. W. Warnes, and M. Y. Morgan, “Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind randomized, dose-finding multi-centre study,” European Journal of Gastroenterology and Hepatology, vol. 12, no. 2, pp. 203–208, 2000.
[11] G. Kircheis, W. E. Fleig, R. Görtelmeyer, S. Grafe, and D. Häussinger, “Assessment of low-grade hepatic encephalopathy:
a critical analysis," *Journal of Hepatology*, vol. 47, no. 5, pp. 642–650, 2007.

[12] J. P. Ong, A. Aggarwal, D. Krieger et al., "Correlation between ammonia levels and the severity of hepatic encephalopathy," *American Journal of Medicine*, vol. 114, no. 3, pp. 188–193, 2003.

[13] A. T. Blei and J. Córdoba, "Hepatic encephalopathy," *American Journal of Gastroenterology*, vol. 96, pp. 1968–1976, 2001.

[14] N. M. Bass, "The current pharmacological therapies for hepatic encephalopathy," *Alimentary Pharmacology & Therapeutics*, vol. 25, supplement 1, pp. 23–31, 2007.

[15] K. Tarao, T. Ikeda, K. Hayashi et al., "Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy," *Gut*, vol. 31, no. 6, pp. 702–706, 1990.

[16] M. L. Zeneroli, R. Avallone, B. L. Corsi, I. Venturini, C. Baraldi, and M. Baraldi, "Management of hepatic encephalopathy: role of rifaximin," *Chemotherapy*, vol. 51, supplement 1, pp. 90–95, 2005.

[17] P. S. Lieman, "Liver disease, aminoglycoside antibiotics and renal dysfunction," *Hepatology*, vol. 8, no. 4, pp. 966–968, 1988.

[18] E. A. Debbia, E. Maioli, S. Roveta, and A. Marchese, "Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations," *Journal of Chemotherapy*, vol. 20, no. 2, pp. 186–194, 2008.

[19] K. R. Lawrence and J. A. Klee, "Rifaximin for the treatment of hepatic encephalopathy," *Pharmacotherapy*, vol. 28, no. 8, pp. 1019–1032, 2008.

[20] D. Festi, G. Mazzella, M. Orsini et al., "Rifaximin in the treatment of chronic hepatic encephalopathy; results of a multicenter study of efficacy and safety," *Current Therapeutic Research*, vol. 54, no. 5, pp. 598–609, 1993.

[21] L. Bucci and G. C. Palmieri, "Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy," *Current Medical Research and Opinion*, vol. 13, no. 2, pp. 109–118, 1993.

[22] P. Massa, E. Vallerino, and M. Dodero, "Treatment of hepatic encephalopathy with rifaximin: double blind, double dummy study versus lactulose," *European Journal of Clinical Research*, vol. 4, pp. 7–18, 1993.

[23] A. Mas, I. Rodés, L. Sunyer et al., "Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial," *Journal of Hepatology*, vol. 38, no. 1, pp. 51–58, 2003.

[24] C. Loguercio, A. Federico, V. De Girolamo, A. Ferrieri, and C. Del Vecchio Blanco, "Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study," *Minerva Gastroenterologica e Dietologica*, vol. 49, no. 1, pp. 53–62, 2003.

[25] G. Fera, F. Agostinachi, M. Nigro, O. Schiraldi, and A. Ferrieri, "Rifaximin in the treatment of hepatic encephalopathy," *European Journal of Clinical Research*, vol. 4, pp. 57–63, 1993.

[26] H. Song, K. S. Lee, M. H. Kim, Y. H. Paik, B. S. Moon, and S. H. Yoon, "The clinical efficacy of rifaximin in the treatment of hepatic encephalopathy (comparison with lactulose)," *Hepatology*, vol. 32, article 407, 2000.

[27] H. O. Conn, C. M. Leevy, Z. R. Vlahcevic et al., "Comparison of lactulose and neomycin in the treatment of chronic portal systemic encephalopathy. A double blind controlled trial," *Gastroenterology*, vol. 72, no. 4, pp. 573–583, 1977.

[28] W. Bleibel and A. M. Al-Osaimi, "Hepatic encephalopathy," *Saudi Journal of Gastroenterology*, vol. 18, no. 5, pp. 301–309, 2012.

[29] Z. D. Jiang and H. L. Dupont, "Rifaximin: in vitro and in vivo antibacterial activity—a review," *Chemotherapy*, vol. 51, no. 1, pp. 67–72, 2005.

[30] N. M. Bass, K. D. Mullen, A. Sanyal et al., "Rifaximin treatment in hepatic encephalopathy," *The New England Journal of Medicine*, vol. 362, no. 12, pp. 1071–1081, 2010.